UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.
NEWS
deCODE Paper in JAMA Describes Efficacy of DG031 in Controlling Key Indicators of Risk for Heart Attack
Reykjavik, ICELAND, May 10, 2005 – deCODE genetics (Nasdaq:DCGN) today announced the publication of a landmark article by a team of its scientists presenting the results of Phase II clinical studies of DG031, the company’s lead compound being developed for the...
deCODE Initiates Enrollment in Phase I Clinical Trial of DG041 for atherosclerosis
Reykjavik, ICELAND, March 9, 2005 – deCODE genetics (Nasdaq:DCGN) today announced that it has begun enrolling subjects in a Phase I clinical trial for DG041, the company’s developmental compound for the treatment of atherosclerosis of the extremeties, commonly known...
Award by the American Society of Human Genetics
At its Annual meeting in October 2017 in Orlando, the American Society of Human Genetics (ASHG), presented Dr. Kári Stefánsson, founder and CEO of deCODE genetics, with the William Allan Award. The award, the top prize given by the society, recognizes a scientist for substantial and far-reaching scientific contributions to human genetics. The ASHG has distributed video footage from the award ceremony. The introduction is given by Professor Mark Daly of Harvard University.